Is Vincerx Pharma, Inc. (VINC) a Buy, Sell, or Hold?
OTC : VINC
Vincerx Pharma, Inc.
$0.0127 USD
$0 (0.0%)
- Volume
- 500
- Average Volume
- 3.83K
- Market Capitalization
- $66.48K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $1.43
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.21
Company Overview
OTC
Raquel E. Izumi
Biotechnology
Healthcare
VINC
13
US
USD
Liquidity Metrics
0.00
1.21
1.21
0.94
0.00
Sales & Valuation
-$
0.00
0.02
0.00
-4.99
Profitability
-$5.75
-$30.07M
0.00%
0.00%
-431.29%
-375.69%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
$3.00
$4.00
$2.00
0/5
7 Analysts
-99.58%
Financial Health Scores
-76.48
3/9
$2.07M
$4.69M
$2.62M
-$27.32M
Key Metrics (TTM)
-$4.92M
0.00
0.16
1.21
-431.29%
-1155.03%
-45240.83%
-39303.50%
-679 days
Company Executives
| Name | Title |
|---|---|
| Alexander A. Seelenberger | Consultant |
| Tom C. Thomas | Consultant |
| Hans-Georg Lerchen | Chief Scientific Officer |
| Kevin Haas | Acting Chief Financial Officer, Vice President of Finance & Corporate Controller |
| Gabriela Jairala | Vice President of Investor Relations & Corporate Communications and Chief of Staff |
| Karen Quarford | Vice President of Quality Operations & Compliance |
| Melissa Merrick SPHR | Senior Director of People & Culture and Head of Human Resource |
| Beatrix Stelte-Ludwig | Executive Chief Development Officer |
| John C. Byrd | Founder & Chairman of Scientific Advisory Board |
| Raquel E. Izumi | Co-Founder, Acting Chief Executive Officer, Secretary & Director |
Poll Results
No votes yet today — be the first to share your view!
About Vincerx Pharma, Inc. (OTC:VINC) Stock
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California. ...
Frequently Asked Questions
-
What is the current Vincerx Pharma, Inc. (VINC) stock price?
-
Vincerx Pharma, Inc.(OTC:VINC) stock price is $0.0127 in the last trading session. During the trading session, VINC stock reached the peak price of $1.43 while $0.001 was the lowest point it dropped to. The percentage change in VINC stock occurred in the recent session was 0.0% while the dollar amount for the price change in VINC stock was $0.
-
VINC's industry and sector of operation?
-
The OTC listed VINC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VINC?
-
Alexander A. Seelenberger | Consultant
Tom C. Thomas | Consultant
Hans-Georg Lerchen | Chief Scientific Officer
Kevin Haas | Acting Chief Financial Officer, Vice President of Finance & Corporate Controller
Gabriela Jairala | Vice President of Investor Relations & Corporate Communications and Chief of Staff -
How many employees does VINC have?
-
Number of VINC employees currently stands at 13. VINC operates from 1825 S Grant Street, Palo Alto, CA 94402, US.
-
Link for VINC official website?
-
Official Website of VINC is: https://vincerx.com
-
How do I contact VINC?
-
VINC could be contacted at phone #650 800 6676 and can also be accessed through its website. VINC operates from 1825 S Grant Street, Palo Alto, CA 94402, US.
-
How many shares of VINC are traded daily?
-
The average number of VINC shares traded daily for last 3 months was 3.83K.
-
What is the market cap of VINC currently?
-
The market value of VINC currently stands at $66.48K with its latest stock price at $0.0127